Legal Weed May Cut Opioid Use for Cancer Pain
Newsweek US|December 16, 2022
A new study says prescriptions are down in states where medical marijuana is available
JESS THOMSON
Legal Weed May Cut Opioid Use for Cancer Pain

THE LEGALIZATION OF MEDICAL marijuana may reduce opioid use in cancer patients.

As of 2022, medical marijuana for pain relief is legal in 37 states and Washington, D.C. Living in these states is associated with a lower rate of opioid dispensing in patients receiving cancer treatments, a paper published on December 1 in the journal JAMA Oncology says.

Results of the study show that medical marijuana legalization was associated with a 5.5 percent to 19.2 percent relative reduction in the rate of opioid dispensing (i.e., the rate of receiving at least one opioid prescription) to adult patients aged 18 to 64 who were newly diagnosed with breast, colorectal or lung cancer and receiving cancer treatment.

The analysis involved 38,189 patients newly diagnosed with breast cancer, 12,816 with colorectal cancer and 7,190 with lung cancer. These three cancer types were chosen for the study because of the large number of new cases among those younger than 65.

Between 2012 and 2017, medical marijuana legalization took effect in 14 states: Arkansas, Connecticut, Florida, Illinois, Louisiana, Maryland, Massachusetts, Minnesota, New Hampshire, New York, North Dakota, Ohio, Pennsylvania and West Virginia.

This story is from the December 16, 2022 edition of Newsweek US.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the December 16, 2022 edition of Newsweek US.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM NEWSWEEK USView All
Ray Romano
Newsweek US

Ray Romano

\"I read about three scripts, and at the end of each there was a little twist, a little turn, [and] it was funny.\"

time-read
2 mins  |
December 27, 2024
Has J.K. Rowling Won the Culture War?
Newsweek US

Has J.K. Rowling Won the Culture War?

After years of backlash over trans issues, the Harry Potter author has received major business backing

time-read
7 mins  |
December 27, 2024
Nothin' Lasts Forever
Newsweek US

Nothin' Lasts Forever

Taylor Swift's Eras Tour' ends its record-breaking run..

time-read
3 mins  |
December 27, 2024
SPY IN THE SKY
Newsweek US

SPY IN THE SKY

CHINA FACES ACCUSATIONS of ESPIONAGE and WEAPONIZING OUTER SPACE as it BUILDS a NEW OBSERVATORY in CHILE critics say WILL BE USED for MILITARY PURPOSES

time-read
10+ mins  |
December 27, 2024
'This Murder Is a Symbol of the Times'
Newsweek US

'This Murder Is a Symbol of the Times'

Conservatives and liberals agree on the state of the health care industry following the killing of Brian Thompson

time-read
3 mins  |
December 27, 2024
The Defense Industry's Fight With ESG
Newsweek US

The Defense Industry's Fight With ESG

EUROPEAN DEFENSE COMPANIES, ESPECIALLY smaller businesses, are being blocked from investment they sorely need by sustainability rules, a senior NATO official and several industry figures have said.

time-read
9 mins  |
December 27, 2024
Margo Martindale
Newsweek US

Margo Martindale

Jamie Lee [Curtis, producer] called me and she says, \"Jamie Lee Curtis here. I have a project for you. And you're gonna do it.\"

time-read
1 min  |
December 20, 2024
Malala Yousafzai
Newsweek US

Malala Yousafzai

\"AFGHANISTAN IS THE ONLY COUNTRY IN THE world where girls are banned from access to education and women are limited from work.\"

time-read
1 min  |
December 20, 2024
In the Eyes of the Law
Newsweek US

In the Eyes of the Law

Jude Law is unrecognizable as an FBI agent on the trail of aneo-Naziterrorist group in real-crime drama The Order

time-read
4 mins  |
December 20, 2024
Gonzo Intelligence
Newsweek US

Gonzo Intelligence

Instead of keeping a low profile, Moscow's spies are embracing the limelight and even being welcomed home by Vladimir Putin after their cover is blown

time-read
7 mins  |
December 20, 2024